Industry Showcase
UZEDY: An LAI With a Spectrum of Key Attributes for the Treatment of Schizophrenia
Supported by Teva Pharmaceutical

1. Understand the role of UZEDY as a long-acting injectable (LAI) treatment option for schizophrenia
2. Discuss the flexible once-monthly and once-every-2-months dosing options of UZEDY
3. Review the attributes of UZEDY, including initiation without loading dose or oral supplementation

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:

• A modern web browser with JavaScript and cookies enabled: Chrome is strongly recommended, or the latest version of Firefox or Safari.
• A PDF reader: Chrome built-in, Firefox built-in, Acrobat or FoxIt
• An adequate device and Internet connection: Processor: Dual-core 2Ghz or higher (Intel i3/i5/i7 or AMD equivalent); Memory: 4 GB; Storage: 5 GB available; Internet speed: 4.0 Mbps (up/down)

AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.